| Literature DB >> 33610552 |
Anutthaman Parthasarathy1, Eli J Borrego1, Michael A Savka1, Renwick C J Dobson2, André O Hudson3.
Abstract
For millennia, humanity has relied on plants for its medicines, and modern pharmacology continues to reexamine and mine plant metabolites for novel compounds and to guide improvements in biological activity, bioavailability, and chemical stability. The rising threat of antibiotic resistance and increasing exposure to viral and parasitic diseases has spurred renewed interest into drug treatments for infectious diseases. In this context, an urgent revival of natural product discovery is globally underway with special attention directed towards the numerous and chemically diverse plant defensive compounds such as phytoalexins and phytoanticipins that combat herbivores, microbial pathogens, or competing plants. Moreover, advancements in "omics", chemistry, and heterologous expression systems have facilitated the purification and characterization of plant metabolites and the identification of possible therapeutic targets. In this review, we describe several important amino acid-derived classes of plant defensive compounds, including antimicrobial peptides (e.g., defensins, thionins, and knottins), alkaloids, non-proteogenic amino acids, and phenylpropanoids as potential drug leads, examining their mechanisms of action, therapeutic targets, and structure-function relationships. Given their potent antibacterial, antifungal, anti-parasitic, and antiviral properties, which can be superior to existing drugs, phytoalexins and phytoanticipins are an excellent resource to facilitate the rational design and development of antimicrobial drugs.Entities:
Keywords: amino acids; antibiotic resistance; plant defense; plants; secondary metabolites
Year: 2021 PMID: 33610552 PMCID: PMC8024917 DOI: 10.1016/j.jbc.2021.100438
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157
A summary of selected examples of the in vitro and in vivo antimicrobial activity of plant-derived AMPs discussed in this article
| AMP family | Prominent examples (plant sources) | Activity (putative mechanism) | Type of testing, target pathogen/infection, reference | Available production methods |
|---|---|---|---|---|
| Cyclotides | CyO2 ( | Antibacterial (membrane binding), antifungal (membrane disruption, spore penetration), antiviral (disruption of viral integrity, pore formation in infected cells) | Animal tests, | Chemical, chemoenzymatic, heterologous |
| Defensins | RsAFP2 ( | Antifungal (reactive oxygen species, elevated septin and ceramide, apoptosis induction; targets cell wall and membrane sphingolipids) | Animal tests (prophylactic), | Chemical, heterologous |
| Thionins | CaThi ( | Antibacterial (membrane disruption), antifungal (membrane disruption, apoptosis, reactive oxygen species) | Chemical, heterologous | |
| Knottins | As1 ( | Antiviral (inhibits viral spike protein and maturation protein) | Mammalian cell culture, influenza B virus ( | Chemical, heterologous |
| Snakin-like peptides | Snakin-Z ( | Antibacterial and antifungal (membrane disruption by pore formation) | Mammalian cell culture, | Chemical, heterologous |
| α-Hairpinin-like peptides | EcAMP1 ( | Antifungal (binding cell wall carbohydrates and membrane lipids) | Chemical, heterologous | |
| Luffin P1 ( | Antiviral (binds the | Mammalian cell culture, HIV-1 ( | ||
| Hevein-like peptides | ( | Antifungal (chitin assembly inhibition, membrane disruption) | Mammalian cell culture, | Chemical, heterologous |
Figure 1Nonprotein amino acids (NPAAs) with anti-infective properties. Mimosine, leucenol or β-[N-(3-hydroxy-4-pyridone)]-aminopropionic acid (antifungal), β-(3-isoxazolin-5-on-2-yl)-alanine or βIA (antifungal), m-Tyrosine (part of antiviral molecules), nicotinic acid (part of bioactive alkaloids), l-canavanine (antibacterial), and azetidine-2-carboxylic acid, l-Aze, or A2C (part of antibacterial and antifungal molecules).
A summary of the in vivo antimicrobial activity of promising alkaloids and organosulfur compounds
| Compound (class, plant source) | Mechanism of action | Target pathogen/infection (reference) | Relevance |
|---|---|---|---|
| α-Chaconine (steroidal glycoalkaloid, Solanaceae) | Suppresses 70% of the parasites over 4 days | Pervasive drug resistance of malarial parasites | |
| Lycorine (phenylethylamine alkaloid, wild daffodil) | Inhibits RNA-dependent RNA polymerase, reduces viral load | Zika virus ( | Approved vaccines/specific antivirals not available |
| Mitigate lung injury, decrease viral load and serum interleukin IL-1β, reduce levels of inflammatory factors, increase serum interleukin 10 and interferon γ | Influenza A virus ( | Improves host immune defenses post infection | |
| Berberine (isoquinoline alkaloid, Berberidaceae) | Globally reduces viral activation of major mitogen-activated protein kinase pathways, reduces viral titer and inflammatory symptoms | Chikungunya virus ( | Attacks multiple targets and suppresses host inflammation |
| MFM501 (synthetic derivative of pyrrolidine alkaloid from | Bacteriostatic against over 40 clinical strains, targets the bacterial membrane | Methicillin-resistant | Clinical strains suppressed with no toxicity |
| Voacamine (indole alkaloid, | Kills parasites by poisoning topoisomerase 1B; does not inhibit human topoisomerases I and II | First molecule active against | |
| Allicin (organosulfur, garlic) | S-allylmercaptyl addition to bacterial cysteine sulfides, depletion of glutathione pools, induction of heat stress response; inhibits diesterases and oxidoreductases, disrupts plasma and endomembranes, promotes apoptosis and cell cycle arrest in parasites (reduces load, kills trophozoites) | Lung pathogenic bacteria, | Only inhalable antibiotic to clear lung infection; resistance to anti-giardial metronidazole rising, poor vaccine availability |
Figure 2The biosynthetic pathway of the tomato alkaloids based on Akiyama (221). The nitrogen incorporation occurs in the earlier phase of the biosynthesis from cholesterol (222). The genes names in tomato are shown as yellow entries, while the blue entries are the enzyme activities. 3βHSD, 3β-hydroxysteroid dehydrogenase; 3KSI, 3-ketosteroid isomerase; S5αR, steroid 5α-reductase; 3KSR, 3-ketosteroid reductase.
Figure 3Selected alkaloids, which have been utilized in .
Figure 4The biosynthetic pathway of camalexin (261) and that of cruciferous indoles (262). The dashed arrows and the square brackets emphasize proposed unstable intermediates. The common names of plants producing some compounds are shown italicized in parentheses.
Figure 5Two possible biosynthetic pathways (Routes 1 and 2) of the linear sulfurous compound allicin from the precursors serine and glutathione based on (276). The immediate precursor of alliin is S-allyl cysteine, which may derive from either serine or glutathione. 14C-Labeled serine feeding experiments led to the formation of 14C-labeled S-allyl-cysteine. However, S-allyl-glutathione and S-allyl-γ-glutamyl-cysteine have been detected in other experiments. The source of the allyl group is unknown for both Routes 1 and 2.
Figure 6The phenylpropanoid pathway, which leads to a variety of plant defensive compounds starting from phenylalanine (298).
A summary of selected in vitro and animal/clinical studies involving phenylpropanoids
| Compound (class) | Mechanism of action | Target pathogen/infection (reference) | Type of study |
|---|---|---|---|
| KIN101 (isoflavone) | Activates interferon regulatory factor IRF-3 | Hepatitis C virus, influenza A virus ( | Cell culture; first small molecule stimulators of the human innate immune system |
| Baicalein (flavonoid) | Synergy with ciprofloxacin kills ciprofloxacin-resistant bacteria | Ciprofloxacin-resistant methicillin resistant | |
| Hymecromone, scoparone (coumarins) | Reactivate latent virus, enable viral clearance by other agents | HIV-1 ( | Cell culture; HIV-1 reservoir eradication, low cytotoxicity |
| (-)-Hopeaphenol | Blocks type III secretion systems in Gram-negative bacteria, prevents growth of | ||
| Arctiin (lignin) | Elicits the production of virus-specific antibodies | Influenza A virus ( | |
| 23-( | Enhanced survival rate of infected mice, 100-fold drop in viral titers in the lungs, modulates inflammatory responses | Influenza A virus ( | |
| Silibinin 2',3-di(sodium succinate) or Legalon SIL | Prevents production of hepatitis C virus, elevates anti-inflammatory responses | Hepatitis C virus ( | |
| Podophyllotoxin (lignan) | Clears anogenital warts with equal efficacy to imiquimod | Human papilloma virus ( | Randomized clinical trial, wart clearance time about 4 weeks compared with 16 weeks for imiquimod |
| Bicyclol (lignan) | Inhibition by upregulation of the glycolipid transfer protein leading to arrest of viral replication, reduces liver inflammation by suppression of mitogen-activated protein kinase/nuclear factor κB signaling | Hepatitis B and hepatitis C viruses ( | Inhibits hepatitis B and hepatitis C viruses without toxic effects, enhances effect of established antivirals; used in China |